Carcinoid heart disease: The rare and obscure becomes screened and well known

Mayberry, John

doi:10.1016/j.amjsurg.2022.02.003

Cited by 2 publications

(2 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These substances cause the deposition of plaque-like fibrous tissue in the endocardium, leading to valve dysfunction and eventual progression to heart failure. [14] After heart failure occurs, the prognosis is severely affected, and the survival period is typically less than 1 year. [15] Unfortunately, although several studies have aimed to quantify the risk of TC tumor-specific death or overall survival, [16,17] few reports have investigated the risk factors for CVM in TC patients, thereby creating difficulties in the precise clinical management of these patients.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Competing risk analysis of cardiovascular-specific mortality in typical carcinoid neoplasms of the lung: A SEER database analysis

Xing,

Wu,

Zhang

et al. 2023

Medicine

View full text Add to dashboard Cite

Cardiovascular mortality (CVM) is a growing concern for cancer survivors. This study aimed to investigate the mortality patterns of individuals with typical carcinoid (TC) tumors, identify independent predictors of CVM, and compare these risk variables with those associated with TC deaths. The Surveillance, Epidemiology, and End Results (SEER) database from 2000 to 2019 was utilized for obtaining data on patients with TC. Standardized mortality rates were employed to evaluate the risk of CVM while multivariate competing risk models were used to determine the association between patient characteristics and the probability of CVM or TC-related deaths. Our findings show that TC patients had an increased risk of CVM, with an standardized mortality rates of 1.12 (95% CI:1.01–1.25). Furthermore, we discovered that age at diagnosis, marital status, year of diagnosis, SEER stage, site, year of diagnosis, surgery, radiotherapy, and chemotherapy all contributed independently to the risk of CVM in patients with TC, whereas age at diagnosis, sex, race, SEER stage, site, year of diagnosis, surgery, radiotherapy, and chemotherapy all contributed significantly to TC mortality. Compared to the general population in the United States, patients with TC are significantly more likely to acquire CVM. Timely introduction of cardioprotective treatments is critical for preventing CVM in patients with TC.

show abstract